The abstract is read at the publisher; the summary is JClub's.
Voriconazole is linked to better overall treatment outcomes than amphotericin B deoxycholate in invasive aspergillosis when assessed with the MSG DOOR framework.
- Why it matters: Mortality alone can miss important aspects of treatment response in invasive aspergillosis, including failure and severe side effects.
- What they did: The randomized controlled trial was reanalyzed using the MSG Desirability of Outcome Ranking (DOOR) framework, combining mortality, treatment failure, and severe adverse events.
- The result: The DOOR-based integration indicates voriconazole provides superior overall outcomes versus amphotericin B deoxycholate, supporting a more comprehensive efficacy assessment.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.